Valuation: Kodiak Sciences Inc.

Market Cap 6.32B 5.73B 5.3B 4.78B 9.02B 590B 9.37B 63.83B 25.25B 318B 23.7B 23.2B 1,006B P/E 2026 *
-24x
P/E 2027 * -25.1x
Enterprise Value 6.17B 5.6B 5.17B 4.66B 8.81B 576B 9.14B 62.3B 24.64B 311B 23.13B 22.65B 982B EV / Sales 2026 *
-
EV / Sales 2027 * 124x
Free-Float
94.8%
Yield 2026 *
-
Yield 2027 * -
1 day-3.90%
1 week-10.42%
Current month-2.40%
1 month+12.89%
3 months+136.21%
6 months+161.48%
Current year+246.21%
1 week 94.62
Extreme 94.62
112.79
1 month 83.16
Extreme 83.1567
112.79
Current year 20.88
Extreme 20.88
112.79
1 year 19.04
Extreme 19.0401
112.79
3 years 1.92
Extreme 1.92
112.79
5 years 1.37
Extreme 1.37
112.79
10 years 1.37
Extreme 1.37
171.21
Manager TitleAgeSince
Chief Executive Officer 53 2008-12-31
Director of Finance/CFO 64 2015-12-31
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Chairman 53 2008-12-31
Director/Board Member 57 2015-08-31
Director/Board Member 55 2018-07-17
Date Insider Type Main position Quantity % Market Cap. Importance
11/5/26
Baker Bros. Advisors LP
BuyCompany 86,432 0.1375%
10/23/26 Exercice

Director

40,000 0.0636%
10/21/26 Exercice

Chief Financial Officer

90,000 0.1432%
Change 5-day change 1-year change 3-year change Capi.($)
-3.90%-10.42%+388.15%+3,787.55% 6.57B
+1.15%-2.81%+55.79%+71.12% 65.56B
-2.64%+0.07%+9.57%+89.87% 60.41B
-1.07%+0.55%+21.79%+87.66% 55.76B
+0.48%-2.53%+9.73%+121.14% 46.98B
-2.69%-6.38%+19.19%+25.79% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.50%-15.73%+135.31%+662.73% 36.09B
-0.77%-4.34%+79.27%+59.47% 32.9B
-0.83%+1.98%-38.27%+390.98% 26.96B
Average -1.35%-2.26%+69.46%+534.15% 41B
Weighted average by Cap. -1.04%-1.69%+39.54%+205.96%

Financials

2026 *2027 *
Net sales - 49.26M 44.72M 41.31M 37.27M 70.36M 4.6B 73.05M 498M 197M 2.48B 185M 181M 7.85B
Net income -258M -235M -217M -195M -369M -24.14B -383M -2.61B -1.03B -13.03B -969M -949M -41.15B -269M -244M -225M -203M -384M -25.11B -398M -2.72B -1.07B -13.55B -1.01B -987M -42.8B
Net Debt -151M -137M -127M -114M -216M -14.13B -224M -1.53B -604M -7.62B -567M -555M -24.09B -231M -210M -194M -175M -330M -21.57B -342M -2.33B -923M -11.64B -866M -848M -36.77B
Projected Income Statement - Annual - Kodiak Sciences Inc.
Logo Kodiak Sciences Inc.
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.
Employees
144
Date Price Change Volume
26-11-17 US$96.80 -3.90% 820,826
26-11-16 US$100.73 -9.41% 980,376
26-11-13 US$111.19 +2.72% 972,262
26-11-12 US$108.25 -1.00% 561,199
26-11-11 US$109.34 +1.18% 689,283
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Kodiak Sciences Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
96.80USD
Average target price
129.50USD
Spread / Average Target
+33.78%